课题基金 / 基金详情

GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM

GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
批准号:
3557655
负责人:
DAVID K KING
金额:
$13.28万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-09-01 至 1993-05-31

项目摘要

项目成果

DAVID K KING的其他基金

相关文献

中文摘要
翻译
大凤凰城社区临床肿瘤学项目 (GPCCOP)代表一个由七家医院和六家医院组成的财团 大都会凤凰城地区的附属医师团体 在图森有一家附属公司。31名调查人员现在已经 被指定管理临床试验中的患者(两者 治疗和癌症控制)。该财团看到了一个新的 癌症患者人数每年超过2,300人, 去年有110多名患者接受了研究。最直接的 GPCCOP的目标包括:增加临床研究 活动;维护高质量的数据支持和药房 资源;继续发展广泛的癌症计划 其中包括初级保健医生;数据的持续支持 协助NCI评估的系统;以及进一步开发和 开展癌症控制活动和试点。 该财团拥有完善的设施和人员,以 用几口井支持癌症的治疗和控制 在教育领域建立了癌症控制活动, 筛查和化学预防。许多癌症控制活动 也存在于GPCCOP的每个组成部分中。 GPCCOP已经证明了管理复杂环境的能力 生产过程中的临床研究和癌症控制活动 高质量的数据。数据管理、协议选择 标准、人员配置、质量控制机制、药房控制 机制、内部审查委员会的联络和结构都已到位,并 支持当前和未来的治疗和癌症的功能 控制活动。
英文摘要
The Greater Phoenix Community Clinical Oncology Program (GPCCOP) represents a consortium of seven hospitals and six groups of affiliated physicians in the metropolitan Phoenix area with one affiliate in Tucson. Thirty-one investigators now have been designated to manage patients on clinical trials (both therapeutic and cancer control). The consortium sees a new cancer patient population in excess of 2,300 per year and has placed over 110 patients on study in the last year. The immediate goals of the GPCCOP include: increased clinical research activity; maintenance of high quality data support and pharmacy resources; continued development of a broad cancer program which involves primary care physicians; continued support of data systems to aid NCI evaluations; and further development and implementation of cancer control activities and trials. The consortium has complete facilities and personnel for supporting cancer treatment and control with several well established cancer control activities in the areas of education, screening and chemoprevention. Many cancer control activities are also present in each of the GPCCOP components. The GPCCOP has demonstrated the ability to manage complex clinical research and cancer control activities while producing high quality data. The data management, protocol selection criteria, staffing, quality control mechanisms, pharmacy control mechanisms, IRB liaison and structure are all in place and functioning to support current and future therapeutic and cancer control activities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
COMMUNITY CLINICAL ONCOLOGY PROGRAM
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM